Analysis

Dogwood Therapeutics, Inc. (DWTX) Stock Analysis

Dogwood Therapeutics, Inc. investors can use 6ix to track stock price context, company news, investor events, webinar replays, and AI-assisted analysis connected to DWTX.

websiteDWTX/analysis/DWTX

Dogwood Therapeutics, Inc.

Dogwood Therapeutics, Inc. investors can use 6ix to track stock price context, company news, investor events, webinar replays, and AI-assisted analysisconnected to DWTX.

Stock profile

Ticker

DWTX

Asset type

Stock

Market cap

$51.8M

Sector

Health Technology

Industry

Pharmaceuticals: Major

Currency

USD

Ticker listings

Dogwood Therapeutics, Inc. may appear across multiple exchanges or ticker formats. 6ix consolidates those listings around the canonical analysis page for discovery.

  • DWTX primary listing

Latest Dogwood Therapeutics, Inc. news

Dogwood Therapeutics Announces Commencement of Halneuron® Chemotherapy Induced Neuropathic Pain Phase 2b Long Term Extension Study

New study to assess Halneuron® pain reduction effect over three months of treatment, additional safety data to bolster planned end of Phase 2 FDA submission package Patients com...

Dogwood Therapeutics Announces First Quarter 2026 Financial Results

- Halneuron® Phase 2b trial in Chemotherapy Induced Neuropathy on track for top-line results in fall 2026 - - FDA acceptance of SP16 Investigational New Drug

Dogwood Therapeutics to Report First Quarter 2026 Financial Results on Thursday, May 14, 2026

ATLANTA, May 07, 2026 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (“Dogwood” or the “Company”), a company that focuses on developing new medicines to treat pai...

Dogwood Therapeutics Announces Worldwide Development and Commercialization Partnership for Anti-Viral Assets with Potential Value up to $...

- PRIDCor Therapeutics Granted Global Development and Commercialization License for IMC-1 and IMC-2 Assets for All Indications, including Fibromyalgia and Long-COVID - - Dogwood...

Dogwood Therapeutics Announces FDA Acceptance of SP16 Investigational New Drug Application for the Treatment of Chemotherapy Induced Pain...

Dogwood licensed SP16 to treat cancer-related pain from partner and regulatory sponsor Serpin Pharma The SP16 Phase 1b trial fully funded by the National

Research sections

Valuation

Review valuation context for Dogwood Therapeutics, Inc..

Future growth

Review future growth context for Dogwood Therapeutics, Inc..

Past performance

Review past performance context for Dogwood Therapeutics, Inc..

Financial health

Review financial health context for Dogwood Therapeutics, Inc..

Dividend

Review dividend context for Dogwood Therapeutics, Inc..

Management

Review management context for Dogwood Therapeutics, Inc..

Ownership

Review ownership context for Dogwood Therapeutics, Inc..

Other information

Review other information context for Dogwood Therapeutics, Inc..

Community

Review community context for Dogwood Therapeutics, Inc..